BEST UNLIMITED TURBO SHORT CERTIFICATE - ELI LILLY & CO | Real-time Borsa Italiana 09:48:17 28/06/2024 BST | ||
| 6.26 EUR | -8.61% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 6.26 | -8.61% |
| 27/06/24 | 6.85 | -8.54% |
| 26/06/24 | 7.49 | +4.17% |
| 25/06/24 | 7.19 | -13.16% |
| 24/06/24 | 8.28 | -7.49% |
Real-time Borsa Italiana
Last update June 28, 2024 at 09:48 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| S36575 | |
| ISIN | DE000SY1RXY3 |
| Date issued | 18/06/2024 |
| Strike | 976.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.06 € |
|---|---|
| Lowest since issue | 6.2 € |
| Spread | 0.23 € |
| Spread % | 3.61% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
909
USD
Average target price
860.5
USD
Spread / Average Target
-5.33%
- Stock Market
- Certificates
- S36575 Certificat
